


Meyer et al. Supplementary Figure S1



Supplementary Figure S1. *Dnmt3a* haploinsufficiency transforms *Flt3*^{ITD} MPN into an AML with clonogenic c-Kit⁺ leukemic stem and progenitors in the spleen. **A**, Kaplan-Meier survival curves (left) and spleen weights (right) of *Flt3*^{+/ITD}*Dnmt3a*^{fl/fl} mice without (black circles) and with *MxCre* (green circles). Table summarizes the number of animals, median survivals, and mean spleen weights of mice in study. Significant differences in survival were evaluated by Log-rank (Mantel-Cox) test and spleen weights by parametric unpaired t-test. **B**, Kaplan-Meier survival curves of recipient mice (n=4/donor) transplanted with equal numbers of total splenocytes purified from three independent primary *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* donor mice (numbered 1800, 1804, and 1809). **C**, Representative images of *Dnmt3a* floxed and deleted alleles by PCR on DNA from individual colonies derived from single c-Kit⁺ *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* splenocytes grown in methylcellulose for 7 days (right three lanes) and tail DNA as control (left lane). **D**, Frequencies \pm SEM of total (left) and c-Kit⁺ (right) splenocytes expressing lymphoid markers CD3 or B220 derived from age-matched WT, *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl}, or *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* mice (at least 3 mice/group). Significant differences between the indicated populations were compared by one-way ANOVA multiple comparisons test (total splenocytes) or by unpaired parametric t-test (c-Kit⁺ splenocytes). **E-F**, Representative flow plots of spleen (**E**), and frequencies \pm SEM (**F**) of bone marrow and spleen CD11b⁺Gr1⁺ myeloid in age-matched wild-type (WT), *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl}, or *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* mice (at least 3 mice/group). Significant differences between the indicated populations were compared across all groups by two-way ANOVA Tukey's multiple comparisons test. Black asterisks indicate significant differences between *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* and WT; red asterisks


indicate significant differences between *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* and *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl}. **G**, Representative flow plots of lineage negative (Lin⁻), Lin⁻c-Kit⁺ (LK) and Lin⁻Sca-1⁺c-Kit⁺ (LSK), and LK common myeloid progenitor (CMP)/ granulocyte-monocyte progenitor (GMP)/ megakaryocyte-erythroid progenitor (MEP) populations in bone marrow from WT, *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl}, or *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* mice. **H-I**, The total cellularity and frequencies \pm SEM of LK, GMP, and LSK populations in bone marrow (**H**) and spleen (**I**) from age-matched WT, *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl}, or *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* mice (at least 5 mice/group). Significant differences between populations were compared across all groups by two-way ANOVA Tukey's multiple comparisons test. **J**, Average \pm SEM number of colonies arising from c-Kit⁺ (black bars) or c-Kit⁻ (white bars) splenocytes from three independent *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* mice after 7 days in methylcellulose. Significant differences were determined by Holm-Šídák multiple comparisons t-tests. In all panels where indicated *p \leq 0.05, **p \leq 0.01, ***p \leq 0.001, and ****p \leq 0.0001.




Supplementary Figure S2. Comparative patterns of differential global DNA

methylation in *DNMT3A*-mutant human and murine AML. A-F, Ideograms depicting regions of differentially hypermethylated (pink) and hypomethylated (green) DNA along each chromosome in human (**A-C**) and murine (**D-F**) samples. Comparisons indicated at the top of each ideogram. Comparing normal human HSC to human *FLT3*-ITD *DNMT3A*-WT AML (**A**) or human *FLT3*-ITD *DNMT3A*-mutant AML (**B**) reveals changes associated with malignancy; however, direct comparison of human *FLT3*-ITD *DNMT3A*-WT AML versus *FLT3*-ITD *DNMT3A*-mutant AML (**C**) reveals concise global changes associated with *DNMT3A* mutation. Similarly, comparison of normal murine LSK with murine *FLT3*-ITD MPN (**D**) or *FLT3*-ITD *Dnmt3a*-mutant AML (**E**) reveals changes associated with *FLT3*-ITD transformation; however, direct comparison of murine *FLT3*-ITD MPN and *FLT3*-ITD *Dnmt3a*-mutant AML (**F**) reveals concise global changes associated with *Dnmt3a* mutation.

A



B



Supplementary Figure S3. Hematopoietic stem cells/progenitor and c-Myc

signatures are upregulated in murine AML. GSEA analyses query of the MSigDB

were performed using descending ranked fold change expression of *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl}

MxCre AML compared to *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} MPN. **A**, Hematopoietic stem


cell/progenitor upregulated gene sets (left and middle) and myeloid cell development

downregulated gene sets (right) were amongst the top-enriched gene sets associated

with genes upregulated in the murine *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* AML compared to

MPN models. **B**, Enrichment for gene sets associated c-Myc regulated targets were

upregulated in murine *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* AML compared to MPN RNA-Seq.



Supplementary Figure S4. DNMT3A rescued murine *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre*

AML hypermethylated regions correspond to HSPC-like populations. A,

Representative histograms of c-Myc (eGFP) expression in the c-Kit⁺ splenocyte fraction from *c-Myc*^{eGFP};*Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* AML (green line) and *c-*

Myc^{eGFP};*Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} MPN (gray line) mice. Average frequency ±SEM (left bar graph) of c-Kit⁺eGFP⁺ and median eGFP fluorescence intensity (right bar graph) in c-

Kit⁺ cells from *c-Myc*^{eGFP};*Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} MPN and *c-Myc*^{eGFP};*Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* AML are reported for at least 3 mice/group. Statistical significance was

evaluated by unpaired parametric t-test (****p≤0.0001). **B,** Representative histogram of

c-Myc (eGFP) expression in murine *c-Myc*^{eGFP};*Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* AML cells

treated with AC220 or vehicle control. **C,** Representative histogram (left) and median

fluorescence intensity (MFI) (right bar graph) of phosphorylated Stat5 (phospho-Stat5)

intracellular flow analyses in c-Kit⁺ cells from *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl} MPN and

Flt3^{ITD/ITD};*Dnmt3a*^{fl/fl} *MxCre* AML are reported for at least 3 mice/group. No statistical

differences were found between AML and MPN for phospho-Stat5 by unpaired

parametric t-test. **D,** Heatmap of scRNA-Seq data showing expression of genes

associated with genomic regions that were hypomethylated in *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl}

MxCre AML (compared to MPN) and hypermethylated upon DNMT3A rescue. Rank cell

order maintained from **Fig. 3A**, and ICGS clusters are shown at the top. **E,** Violin plots

of *Cxxc5*, *Gata3*, and *Hdac7* from panel **D** for the mean gene expression differences in

each of the ICGS clusters. **F,** Average ±SEM expression of *Cxxc5*, *Emilin2*, and *Il18r1*

in corresponding shRNA or non-targeting (NT) control transduced *Flt3*^{ITD/ITD};*Dnmt3a*^{fl/fl}

MxCre AML cells derived from two independent tumors (mouse AML # 5331; white

bars, mouse AML # 5332;gray bars). Expression is shown as relative to NT control for each mouse. *Sdha* served as loading control. Significance was evaluated by unpaired parametric t-test compared to the NT control for each mouse, respectively (* $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$).

Supplementary Table Legends

Supplementary Table S1. Peripheral blood findings in moribund *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* *MxCre* mice and age-matched *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* and wild-type control mice.

Supplementary Table S2. Frequencies of monocyte and myelomonocytic populations in the bone marrow and spleen of *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* *MxCre* mice and age-matched *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* and wild-type control mice by flow cytometric analyses.

Supplementary Table S3. Differentially methylated regions (DMR) in human *FLT3*-ITD/*DNMT3A*-mut versus *FLT3*-ITD/*DNMT3A*-wt AML and in murine *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* *MxCre* AML versus *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* MPN control mice. Lists of AML-unique and HSPC-like DMR associated genes in human and mouse based on DMRs found only in the *Dnmt3a* mutant AML groups or DMRs in *Dnmt3a* mutant AML with similar methylation patterns to normal HSC.

Supplementary Table S4. RNA-Seq gene expression analyses of *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* *MxCre* AML versus *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* MPN and comparison of differentially expressed genes to human *FLT3*-ITD/*DNMT3A*-mut gene expression and murine AML DMR by GSEA. Lists of AML-unique and HSPC-like genes in human and mouse based on deregulated gene expression found only in the *Dnmt3a* mutant AML groups or deregulated gene expression in *Dnmt3a* mutant AML with similar deregulation patterns to normal HSC.

Supplementary Table S5. ICGS HOPACH gene expression clustering results performed on RNA-Seq data from 96 single *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* *MxCre* AML cells.

Supplementary Table S6. DMR in DNMT3A rescued c-Kit+ *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* *MxCre* cells versus c-Kit+ *Flt3^{ITD/ITD};Dnmt3a^{fl/fl}* *MxCre* empty vector control cells.

Supplementary Table S7. Clinical mutation data on primary human AML samples.